Accelus received a significant financial investment through a $20 million debt facility. This strategic funding will support aggressive salesforce expansion into previously underpenetrated markets and accelerate the company’s clinical research and product development efforts, especially around its flagship FlareHawk and innovative Toro expandable interbody fusion systems.
The funding will also bolster Accelus’ renewed focus on its Adaptive Geometry technology, an advanced feature of its flagship FlareHawk Interbody Fusion System, by facilitating additional clinical studies and data collection. FlareHawk’s unique has demonstrated favorable fusion and patient outcomes in previously published clinical reports, demonstrating the cage’s ability to conform to patients’ endplate geometry with zero cases of device subsidence (defined as an overlap between the vertebral endplates and the device exceeding 25% of the device height). This strategic investment in further research and data analysis is expected to reinforce the clinical efficacy of the FlareHawk system.
Accelus received a significant financial investment through a $20 million debt facility. This strategic funding will support aggressive salesforce expansion into previously underpenetrated markets and accelerate the company’s clinical research and product development efforts, especially around its flagship FlareHawk and innovative Toro expandable...
Accelus received a significant financial investment through a $20 million debt facility. This strategic funding will support aggressive salesforce expansion into previously underpenetrated markets and accelerate the company’s clinical research and product development efforts, especially around its flagship FlareHawk and innovative Toro expandable interbody fusion systems.
The funding will also bolster Accelus’ renewed focus on its Adaptive Geometry technology, an advanced feature of its flagship FlareHawk Interbody Fusion System, by facilitating additional clinical studies and data collection. FlareHawk’s unique has demonstrated favorable fusion and patient outcomes in previously published clinical reports, demonstrating the cage’s ability to conform to patients’ endplate geometry with zero cases of device subsidence (defined as an overlap between the vertebral endplates and the device exceeding 25% of the device height). This strategic investment in further research and data analysis is expected to reinforce the clinical efficacy of the FlareHawk system.
Copy to clipboard 
